Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 925 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HEPATITIS C Clear all
Completed Not applicable Interventional Results available

Helping Empower Liver and Kidney Patients

NCT03426787
View directory record Official record
Conditions
Hepatitis C, Chronic Kidney Diseases, Patient Education
Interventions
Decision Aid
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Not applicable Interventional

Optimizing Kidney Transplant Informed Consent

NCT01859884
View directory record Official record
Conditions
End-stage Kidney Disease
Interventions
Inform Me: web-based education tool
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 1 Interventional

Expanding the Pool in Lung Transplantation

NCT03377478
View directory record Official record
Conditions
Hepatitis C, Lung Transplant
Interventions
Epclusa
Drug
Lead sponsor
Pablo Sanchez
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 1 Interventional

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C

NCT00343525
View directory record Official record
Conditions
Hepatitis C
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Sarasota, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Not applicable Interventional Results available

Computer-based Intervention for Alcohol-using HIV/HCV+ Women

NCT03362476
View directory record Official record
Conditions
Human Immunodeficiency Virus, Hepatitis C, Alcohol Abuse
Interventions
Computer-based alcohol reduction intervention, Brief clinician-delivered MET, Standard of care
Behavioral
Lead sponsor
New York University
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 3, 2026, 11:38 AM EDT
Completed No phase listed Observational

Virology Follow up Study in Subjects Previously Treated With Telaprevir

NCT00916474
View directory record Official record
Conditions
Hepatitis C
Interventions
telaprevir
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
25
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 4 Interventional Results available

Maraviroc Efficacy for Hepatitis C

NCT02881762
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus
Interventions
Maraviroc
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

NCT02593162
View directory record Official record
Conditions
Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 4
Interventions
Faldaprevir, TD-6450, Ribavirin
Drug
Lead sponsor
Trek Therapeutics, PBC
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 1 Interventional

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects

NCT00142103
View directory record Official record
Conditions
Hepatitis, Chronic Active
Interventions
CPG10101, Control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Miami, Florida • Chicago, Illinois • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated May 15, 2011 · Synced Sep 3, 2026, 11:38 AM EDT
Completed No phase listed Observational

Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV

NCT00004846
View directory record Official record
Conditions
Hepatitis C, HIV Infection
Interventions
ABC/Gen-Probe/Chiron HIV-1/HCV 001
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

NCT00725803
View directory record Official record
Conditions
HCV Infection
Interventions
GS-9450, GS-9450 Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Anaheim, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

NCT01728324
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
31
States / cities
North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

NCT01483742
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Anaheim, California • Coronado, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

NCT00726882
View directory record Official record
Conditions
HCV Infection
Interventions
Blood sample collection only, ABT-333
Procedure · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Anaheim, California • Los Angeles, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

NCT01591668
View directory record Official record
Conditions
Hepatitis C
Interventions
Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant

NCT02165189
View directory record Official record
Conditions
Hepatitits C
Interventions
Simeprevir, Sofosbuvir, Ribavirin
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Aurora, Colorado • Gainesville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790
View directory record Official record
Conditions
Hepatitis C
Interventions
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Not applicable Interventional Results available

TeleHepC Treatment Trial

NCT04798521
View directory record Official record
Conditions
Hepatitis C
Interventions
Tele-HCV, Community Linkage to Care
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Portland, Oregon • Roseburg, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 1Phase 2 Interventional

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

NCT04596475
View directory record Official record
Conditions
Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Interventions
glecaprevir/pibrentasvir (GLE/PIB)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections

NCT00001035
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Interferon alfa-2b, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
3
States / cities
Los Angeles, California • Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 3, 2026, 11:38 AM EDT
Terminated No phase listed Observational

Prediction of Hepatitis C Recurrence in Liver Transplant Recipients

NCT00867243
View directory record Official record
Conditions
Complication of Transplanted Liver, Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Sep 3, 2026, 11:38 AM EDT
Terminated Phase 1 Interventional

Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

NCT00277758
View directory record Official record
Conditions
Hepatitis C
Interventions
Interleukin 2, Ribavirin, Pegylated Interferon Alpha, Inteleukin-2, Ribavirin + Pegylated interferon-alpha
Biological · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

NCT00758043
View directory record Official record
Conditions
Hepatitis C
Interventions
telaprevir, ribavirin, peginterferon alfa-2a
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience

NCT02745535
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Sofosbuvir/Velpatasvir/Voxilaprevir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 3, 2026, 11:38 AM EDT